This might be a theoretical argument for IL-6 inhibition as a therapeutic approach in SLE patients, using biologics to target IL-6 or its receptor or the administration of JAK inhibitors to target JAK molecules attached to the IL-6 receptor. This evidence concerns the gene IL6 and systemic lupus erythematosus.